Perrigo Company plc and Merus N.V.: SG&A Spending Patterns Compared

SG&A Spending Patterns: A Tale of Two Companies

In the world of pharmaceuticals, understanding spending patterns can reveal much about a company's strategy and market position. Perrigo Company plc, a global leader in over-the-counter health products, and Merus N.V., a clinical-stage immuno-oncology company, present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.

Perrigo's SG&A expenses have shown a steady increase, peaking at approximately $1.27 billion in 2023, reflecting a strategic investment in expanding its market reach and operational efficiency. This represents a 47% increase from 2014. In contrast, Merus N.V.'s SG&A expenses, while significantly lower, have grown exponentially by over 1,400% during the same period, reaching nearly $60 million in 2023. This surge underscores Merus's aggressive push in research and development, crucial for its growth in the competitive biotech sector.

These spending patterns highlight the distinct paths these companies are taking in their respective markets, offering valuable insights for investors and industry analysts.